Skip to main content

Branded

  • FDA approves Novartis acute myeloid leukemia drug

    WASHINGTON — The Food and Drug Administration on Friday approved Novartis’ Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.

  • Radius Health’s Tymlos earns FDA approval

    WASHINGTON — The Food and Drug Administration on Friday approved Tymlos (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy, manufacturer Radius Health said in a statement. In postmenopausal women with osteoporosis, Tymlos is intended to reduce the risk of vertebral and nonvertebral fractures.

  • ShopRite joins Aetna’s national network of preferred pharmacies

    KEASBEY, N.J. — ShopRite has joined Aetna’s national network of preferred pharmacies. Effective immediately, Aetna Medicare members with drug coverage can fill their prescriptions at preferred copay levels at any ShopRite pharmacy.

    According to ShopRite, this means Aetna Medicare customers can get their prescriptions at low, preferred cost shares while they shop at ShopRite pharmacies.

  • Stivarga receives expanded approval to include hepatocellular carcinoma

    WASHINGTON — The Food and Drug Administration on Thursday expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. The drug, manufactured by Bayer HealthCare Pharmaceuticals, is the first FDA-approved treatment for a liver cancer in almost a decade.
     

  • FDA approves first drug for specific form of Batten disease

    WASHINGTON — The Food and Drug Administration on Thursday approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. BioMarin Pharmaceuticals’ Brineura is the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

  • Branded thiotepa shipped by Amneal

    PATERSON, N.J. — Amneal Biosciences, the exclusive U.S. distributor for Tepadina, on Thursday began shipping the branded thiotepa. The product is available for purchase through major wholesalers and distributors.

  • Rite Aid CEO: Ongoing Walgreens merger affected Q4 earnings

    CAMP HILL, Pa. — Although Rite Aid affirmed it believes its acquisition by Walgreens Boots Alliance is in the “best interest of Rite Aid shareholders, customers and associates,” Chairman and CEO John Standley acknowledged “the extended duration of the merger process is having a negative impact on our results.

  • Upsher-Smith to sell generics business for $1.05B

    MAPLE GROVE, Minn. — Japanese generic pharmaceutical manufacturer Sawai Pharmaceutical will purchase the generic pharmaceuticals business of Upsher-Smith Laboratories, from its parent, Acova, for $1.05 billion.

    Under Thursday’s agreement, expected to close near the end of June 2017, Rusty Field, the current President of Upsher-Smith, will continue leading the company. Following the closing, Upsher-Smith’s non-generic pharmaceuticals businesses will remain with Acova.

X
This ad will auto-close in 10 seconds